Skip to content

Sonoguided-microwave Uterine Myoma

Efficacy Evaluation of Laparoscopic Sonoguided-microwave Uterine Myoma Ablation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05129956
Acronym
myoma
Enrollment
20
Registered
2021-11-22
Start date
2021-08-06
Completion date
2024-12-31
Last updated
2021-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstetric/Gynecology

Keywords

microwave, uterine myoma

Brief summary

This study mainly evaluates the resolution of uterine fibroids by microwave ablation. The medical equipment used is Ke Hui. The Ampening ablation system is a percutaneous surgery. During laparoscopic surgery, it is directly ablated and soft, including problems that cannot be solved by partial or complete tissue ablation. Hydrogen is used. If the expected range of ablation can be found, there is no need to wait for 3 to 6 months for ablation slowly like Haifu surgery. A fast, small, high-quality treatment that provides reference for medical treatment and helps doctors choose the most suitable treatment.

Detailed description

A collection of 20 women suffering from uterine fibroids were treated with microwave fibroids ablation for symptoms of uterine fibroids, and they could be discharged the next day or two days after surgery. Schedule return visits and routine blood tests according to clinical needs, and follow up with ultrasound and questionnaires during routine return visits (1, 3, and 6 months) after surgery. In the third month after surgery, there will be another imaging report. Magnetic resonance imaging and blood tests are used to compare the changes of patients' fibroids, their physiological recovery status, and the degree of improvement in their quality of life.

Interventions

DEVICECovidien Emprint Ablation System with Thermosphere Technology

The ablation time and wattage are determined according to the size of the tumor. The wattages are respectively 45W, 75W, and 100W, and the maximum time is 10 minutes

Sponsors

Kaohsiung Medical University Chung-Ho Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

1. Women who have reached the age of 20 and have not yet menopause. 2. Myoma size≧4cm. 3. Patients with submucosal fmyoma or intramural myoma of the uterus.

Exclusion criteria

1. Patients with subserosal myoma. 2. Pregnant, breastfeeding or have menopause. 3. Pelvic infections, vaginitis, cervicitis or endometritis and have not been cured. 4. Malignant diseases of the cervix and uterus. 5. Abnormal reports of clinical significance in Pap smear or thin-layer cell test. 6. Abnormal blood coagulation function or liver and kidney function, with bleeding tendency. 7. There is no safe puncture treatment route. 8. Those who have installed intrauterine contraceptive device or Pacemaker. 9. Those who cannot perform vaginal ultrasound, such as those who have no sexual experience and do not accept hymen repair.

Design outcomes

Primary

MeasureTime frameDescription
Uterine myoma ablation1 momthThe ablation range of fibroids can be reduced by 50%, measured by MRI cubic centimeter volume.
Improve bleeding3 momthsThe hemoglobin changes before and 3 months after the operation are used to evaluate the improvement of patients' bleeding problems.

Secondary

MeasureTime frameDescription
Reduce days in hospital6 momthsReduce the number of hospitalization days for patients to be less than or equal to 4 days.

Countries

Taiwan

Contacts

Primary ContactCheng-Yu Long, Professor
urolong@yahoo.com.tw+886-7-3121101

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026